Thrombolytic therapy is the only available medical treatment for acute ischemic stroke that has been proven to be effective. Intravenously administered recombinant tissue plasminogen activator (rtPA) has been shown to improve the long-term functional outcome and is recommended for the treatment of eligible acute stroke patients. However, due to the risk of major bleeding, particularly in the brain, patients need to be carefully selected on the basis of eligibility criteria. These have
been largely adopted from the inclusion and exclusion criteria used in the randomized clinical trials.